# LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)

> **NCT01464086** · PHASE3 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 107 (actual)

## Conditions studied

- Li Fraumeni Syndrome

## Interventions

- **OTHER:** whole body MRI

## Key facts

- **NCT ID:** NCT01464086
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-27
- **Primary completion:** 2017-03-31
- **Final completion:** 2017-10-09
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2021-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01464086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01464086, "LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01464086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*